CBD vs CBDV: Main Differences

Although they share most of their acronyms, CBD and CBDV are not the same. These two cannabinoids differ in their structure, effects and properties. However, they also have some similarities. For example, both are found naturally in cannabis. Today in our CBD blog we tell you how they differ, you will discover clearly how they act in the body, what their benefits are and why choosing the right buds can make a difference in your experience.

Key differences between CBD and CBDV

CBD and CBDV are natural cannabinoids that do not produce psychoactive effects in the body.

The big difference we found is that CBD is present in high amounts in almost all cannabis strains, especially in CBD flowers, while CBDV appears in significant amounts only in strains specifically selected to be rich in CBDV.

Discover the New CBDV Flower VELVET by Cannactiva

CBD and CBDV: Origin

Both CBD and CBDV cannabinoids are found naturally in the cannabis plant, in the resin found in the trichomes of the buds.

CBD is found in a generalized way in most CBD and THC strains, while CBDV appears only in genetically selected cannabis strains, and always in a lower concentration than CBD. This difference is due to variations in the side chain during its natural synthesis process.

Chemical structure of CBD and CBDV: Differences

CBD and CBDV have a different structure and chemical formula. Their molecules differ in the length of the side chain: CBD has a side chain of five carbon atoms (pentyl), while CBDV has one of three atoms (propyl). This variation, although subtle, affects how each compound behaves in the body, modifying aspects such as its absorption, interaction with the receptors of the endocannabinoid system and effects on the body.

In chemical terms, the fact that the side chain is shorter in CBDV means that CBD has two more carbon atoms and four more hydrogens than CBDV. That is, CBD has the chemical formula C21H30O2, while CBDV has the formula C19H26O2.

CBD and CBDV: Effects on the body

Both CBD and CBDV cannabinoids are non-psychoactive and act on the endocannabinoid system.

• CBD modulates various receptors in the body, beyond those of the endocannabinoid system. It has been investigated for its anti-inflammatory, analgesic, pain and anxiety properties, mainly. It is also investigated for its neuroprotective and antioxidant effects.
• CBDV acts in a similar but different way. It has been found to share properties with CBD, such as its anti-inflammatory capacity , analgesic and anticonvulsant effects. But its structure allows it to interact differently from CBD, which seems to offer specific benefits. Specifically, the potential of CBDV in the treatment of autism is being investigated.

CBD and CBDV: Benefits and Applications

CBD is widely recognized for its ability to relieve pain, decrease inflammation and anxiety.

Benefits of CBD

CBDV, on the other hand, is being investigated for its potential in the treatment of epilepsy, autism, muscular dystrophy and nausea. Although studies on CBDV are still preliminary, the results obtained are promising. However, there is little research on CBDV and more evidence is still needed to confirm its therapeutic applications.

Note: This information is for informational purposes only and is not a substitute for medical advice. It is not intended to diagnose, prevent or treat any disease or symptom. Cannactiva products are not medicines and are intended for external use.

CBD and CBDV: Availability and Extraction

CBD is easy to obtain due to its presence in most cannabis strains. However, the low concentration of CBDV in the plant makes its extraction difficult.

At Cannactiva, we have Cannactiva’s exclusive CBDV VELVET flower, specially cultivated to offer high levels of both CBD and CBDV cannabinoids.

Legality and Security

Both cannabinoids have a broad safety profile and are legal in most countries as long as THC limits are respected.

Frequently Asked Questions about CBD and CBDV

Discover one of the few hemp genetics rich in CBDV and CBD: the exclusive CBDV Flower VELVET from Cannactiva.

At Cannactiva we are committed to quality and innovation, that’s why we offer you an exclusive CBD flower, of Premium quality, rich in CBD and CBDV, so you can experience and enjoy the best that nature has to offer.

References

1. Merkus F. W. (1971). Cannabivarin and tetrahydrocannabivarin, two new constituents of hashish. Nature, 232(5312), 579-580. https://doi.org/10.1038/232579a0
2. Chiurchiù, E., Sampaolesi, S., Allegrini, P., Ciceri, D., Ballini, R., & Palmieri, A. (2021). A Novel and Practical Continuous Flow Chemical Synthesis of Cannabidiol (CBD) and its CBDV and CBDB Analogues. European Journal of Organic Chemistry. (8), p. 1286-1289, https://doi.org/10.1002/ejoc.202001633.
3. Zamberletti, E., Gabaglio, M., Woolley-Roberts, M., Bingham, S., Rubino, T., & Parolaro, D. (2019). Cannabidivarin Treatment Ameliorates Autism-Like Behaviors and Restores Hippocampal Endocannabinoid System and Glia Alterations Induced by Prenatal Valproic Acid Exposure in Rats. Frontiers in cellular neuroscience, 13, 367. https://doi.org/10.3389/fncel.2019.00367
4. Iannotti, F. A., Pagano, E., Moriello, A. S., Alvino, F. G., Sorrentino, N. C., D’Orsi, L., Gazzerro, E., Capasso, R., De Leonibus, E., De Petrocellis, L., & Di Marzo, V. (2019). Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice. British journal of pharmacology, 176(10), 1568-1584. https://doi.org/10.1111/bph.14460
5. Amada, N., Yamasaki, Y., Williams, C. M., & Whalley, B. J. (2013). Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression. PeerJ, 1, e214. https://doi.org/10.7717/peerj.214
6. Husni, A. S., McCurdy, C. R., Radwan, M. M., Ahmed, S. A., Slade, D., Ross, S. A., ElSohly, M. A., & Cutler, S. J. (2014). Evaluation of Phytocannabinoids from High Potency Cannabis sativa using In Vitro Bioassays to Determine Structure-Activity Relationships for Cannabinoid Receptor 1 and Cannabinoid Receptor 2. Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 23(9), 4295-4300. https://doi.org/10.1007/s00044-014-0972-6
7. Navarro, G., Varani, K., Lillo, A., Vincenzi, F., Rivas-Santisteban, R., Raïch, I., Reyes-Resina, I., Ferreiro-Vera, C., Borea, P. A., Sánchez de Medina, V., Nadal, X., & Franco, R. (2020). Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB1, CB2 and CB1/CB2 heteromer receptors. Pharmacological research, 159, 104940. https://doi.org/10.1016/j.phrs.2020.104940
8. De Petrocellis, L., Starowicz, K., Moriello, A. S., Vivese, M., Orlando, P., & Di Marzo, V. (2007). Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB(1) receptors and endovanilloids. Experimental cell research, 313(9), 1911-1920. https://doi.org/10.1016/j.yexcr.2007.01.008
9. Anavi-Goffer, S., Baillie, G., Irving, A. J., Gertsch, J., Greig, I. R., Pertwee, R. G., & Ross, R. A. (2012). Modulation of L-α-lysophosphatidylinositol/GPR55 mitogen-activated protein kinase (MAPK) signaling by cannabinoids. The Journal of biological chemistry, 287(1), 91-104. https://doi.org/10.1074/jbc.M111.296020
10. Oyagawa, C. R. M., & Grimsey, N. L. (2021). Cannabinoid receptor _CB1 and _CB2 interacting proteins: Techniques, progress and perspectives. Methods in cell biology, 166, 83-132. https://doi.org/10.1016/bs.mcb.2021.06.011
11. Perucca E (2017). Cannabinoids in the Treatment of Epilepsy: Hard Evidence at Last?. Journal of Epilepsy Research, 7(2), 61-76. https://doi.org/10.14581/jer.17012
12. Brodie, M. J., Czapinski, P., Pazdera, L., Sander, J. W., Toledo, M., Napoles, M., Sahebkar, F., Schreiber, A., & GWEP1330 Study Group (2021). A Phase 2 Randomized Controlled Trial of the Efficacy and Safety of Cannabidivarin as Add-on Therapy in Participants with Inadequately Controlled Focal Seizures. Cannabis and Cannabinoid Research, 6(6), 528-536. https://doi.org/10.1089/can.2020.0075
13. Pretzsch, C. M., Floris, D. L., Voinescu, B., Elsahib, M., Mendez, M. A., Wichers, R., Ajram, L., Ivin, G., Heasman, M., Pretzsch, E., Williams, S., Murphy, D. G. M., Daly, E., & McAlonan, G. M. (2021). Modulation of striatal functional connectivity differences in adults with and without autism spectrum disorder in a single-dose randomized trial of cannabidivarin. Molecular autism, 12(1), 49. https://doi.org/10.1186/s13229-021-00454-6
14. Zamberletti, E., Rubino, T., & Parolaro, D. (2021). Therapeutic potential of cannabidivarin for epilepsy and autism spectrum disorder. Pharmacology & therapeutics, 226, 107878. https://doi.org/10.1016/j.pharmthera.2021.107878
15. Scutt, A., & Williamson, E. M. (2007). Cannabinoids stimulate fibroblastic colony formation by bone marrow cells indirectly via CB2 receptors. Calcified tissue international, 80(1), 50-59. https://doi.org/10.1007/s00223-006-0171-7
16. Rock, E. M., Bolognini, D., Limebeer, C. L., Cascio, M. G., Anavi-Goffer, S., Fletcher, P. J., Mechoulam, R., Pertwee, R. G., & Parker, L. A. (2012). Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. British journal of pharmacology, 165(8), 2620-2634. https://doi.org/10.1111/j.1476-5381.2011.01621.x
17. Yang, F., Liu, J., Gu, Y., Jiao, R., Yan, J., Gao, S., Lin, X., & van der Veen, S. (2022). Antimicrobial Activity of Auranofin, Cannabidivarin, and Tolfenamic Acid against Multidrug-Resistant Neisseria gonorrhoeae. Microbiology spectrum, 10(6), e0395222. https://doi.org/10.1128/spectrum.03952-22
18. Hurley, E. N., Ellaway, C. J., Johnson, A. M., Truong, L., Gordon, R., Galettis, P., Martin, J. H., & Lawson, J. A. (2022). Efficacy and safety of cannabidivarin treatment of epilepsy in girls with Rett syndrome: A phase 1 clinical trial. Epilepsia, 63(7), 1736-1747. https://doi.org/10.1111/epi.17247